
Prothena (PRTA) Stock Forecast & Price Target
Prothena (PRTA) Analyst Ratings
Bulls say
Prothena Corp PLC's clinical pipeline shows promising results in reducing amyloid levels with its investigational therapeutics, positioning the company favorably in the treatment landscape for neurodegenerative and rare diseases. The company has guided that it is on track to potentially earn up to $105 million in aggregate milestones by 2026, driven by advancements in its partnered programs with Novo Nordisk and Bristol-Myers Squibb. Additionally, despite some concerns related to elevated ARIA incidence in one of its treatments, the overall tolerability and low incidence of injection-site reactions bodes well for patient compliance and market acceptance of its therapies.
Bears say
Prothena Corp faces several significant challenges that contribute to a negative outlook on its stock. The company is expected to continue incurring net losses until product approval and commercialization, likely requiring additional capital which could dilute shareholder value. Furthermore, uncertainties surrounding regulatory approvals and potential changes to the regulatory landscape pose additional risks that could hinder the company's progress and financial performance.
This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.
Prothena (PRTA) Analyst Forecast & Price Prediction
Start investing in Prothena (PRTA)
Order type
Buy in
Order amount
Est. shares
0 shares